Oncomed Pharmaceuticals (OMED) announced the pricing of its public offering of 5.5M shares of common stock at $10. Underwriters to the offering have been granted an option to purchase an additional 825,000 shares to cover for over-allotment, if any. Net proceeds from the offering will be used for general corporate purposes.